Provided by Tiger Fintech (Singapore) Pte. Ltd.

Larimar Therapeutics, Inc.

3.44
-0.0200-0.58%
Post-market: 3.500.0600+1.74%19:05 EDT
Volume:1.16M
Turnover:4.04M
Market Cap:220.26M
PE:-2.31
High:3.55
Open:3.52
Low:3.40
Close:3.46
Loading ...

Analysts Offer Insights on Healthcare Companies: Bausch Health Companies (BHC), Humana (HUM) and Larimar Therapeutics (LRMR)

TIPRANKS
·
01 May

Larimar Therapeutics Q1 EPS $(0.46) Misses $(0.42) Estimate

Benzinga
·
30 Apr

BRIEF-Larimar Therapeutics Q1 Net Income USD -29.281 Million

Reuters
·
30 Apr

Larimar Therapeutics Reports First Quarter 2025 Financial Results

GlobeNewswire
·
30 Apr

Is Larimar Therapeutics (NASDAQ:LRMR) In A Good Position To Invest In Growth?

Simply Wall St.
·
28 Mar

Larimar Therapeutics Price Target Maintained With a $26.00/Share by Guggenheim

Dow Jones
·
25 Mar

Larimar Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
25 Mar

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Opthea Limited Sponsored ADR (OPT) and Larimar Therapeutics (LRMR)

TIPRANKS
·
25 Mar

William Blair Sticks to Their Buy Rating for Larimar Therapeutics (LRMR)

TIPRANKS
·
25 Mar

Wedbush Cuts Price Target on Larimar Therapeutics to $17 From $22, Maintains Outperform Rating

MT Newswires Live
·
24 Mar

Larimar Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
24 Mar

Larimar Therapeutics Q4 2024 GAAP EPS $(0.45) Misses $(0.32) Estimate, Cash $183.5M

Benzinga
·
24 Mar

BRIEF-Larimar Therapeutics Q4 Net Income USD -28.824 Million

Reuters
·
24 Mar

Larimar Therapeutics Provides Nomlabofusp Development Update and Reports Fourth Quarter and Full Year 2024 Financial Results

GlobeNewswire
·
24 Mar

Larimar Therapeutics Inc expected to post a loss of 32 cents a share - Earnings Preview

Reuters
·
14 Mar

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
11 Mar

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
07 Mar

Larimar Therapeutics (LRMR) Gets a Buy from JMP Securities

TIPRANKS
·
19 Feb

Insiders Re-Evaluate Their US$522.0k Stock Purchase As Larimar Therapeutics Falls To US$215m

Simply Wall St.
·
12 Feb